P740: PK, PD AND SAFETY OF FIRST-IN-HUMAN, FIRST-IN-CLASS PHASE I TRIAL (AUR103-101; BHARAT) OF AUR103, AN ORAL CD47 INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES

Detalles Bibliográficos
Autores principales: Krishnappa, Manjunath, Mandavia, Divyesh, Jain, Minish, S, Mukesh, Patel, Ankit, Agarwal, Anshul, Giri, Sanjeev, Kumar Tiwari, Nirbhay, Thiyagarajan, Saravanan, Dey, Mamon, Padmanabha Naidu, Gutta, Ramachandra, Murali, Kumar, Akhil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Posters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429211/
http://dx.doi.org/10.1097/01.HS9.0000969864.18372.7f

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429211/
http://dx.doi.org/10.1097/01.HS9.0000969864.18372.7f

Ejemplares similares